93 related articles for article (PubMed ID: 7932517)
1. Efficacy and safety of pravastatin in hypertensive hypercholesterolaemic patients on antihypertensive drug therapy.
Celis H; Lijnen P; Fagard R; Staessen J; Thijs L; Amery A
J Hum Hypertens; 1994 Jul; 8(7):525-30. PubMed ID: 7932517
[TBL] [Abstract][Full Text] [Related]
2. The effectiveness and safety of low dose pravastatin in elderly hypertensive hypercholesterolemic subjects on antihypertensive therapy.
Chan P; Lee CB; Lin TS; Ko JT; Pan WH; Lee YS
Am J Hypertens; 1995 Nov; 8(11):1099-104. PubMed ID: 8554733
[TBL] [Abstract][Full Text] [Related]
3. Changes in plasma lipids, lipoproteins and apolipoproteins in hypercholesterolaemic patients treated with pravastatin.
Lijnen P; Celis H; Desager JP; Fagard R
J Hum Hypertens; 1995 Jul; 9(7):557-64. PubMed ID: 7562885
[TBL] [Abstract][Full Text] [Related]
4. Influence of cholesterol-lowering on plasma membrane lipids and function.
Lijnen P; Echevaría-Vázquez D; Petrov V
Methods Find Exp Clin Pharmacol; 1996 Mar; 18(2):123-36. PubMed ID: 8740244
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II.
Arch Intern Med; 1993 Jun; 153(11):1321-9. PubMed ID: 8507122
[TBL] [Abstract][Full Text] [Related]
6. [Pravastatin in the treatment of primary hypercholesterolemia: a Swiss multicenter study].
Ferrari P; Weidmann P; Riesen WF; Martius F; Luban S; Pasotti E; Erne P; Fragiacomo C; Noseda G; Reutter F
Schweiz Med Wochenschr; 1993 Sep; 123(37):1736-41. PubMed ID: 8211024
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of pravastatin once daily in primary moderate hypercholesterolemia: the Israeli experience.
Beigel Y; Brook G; Eisenberg S; Fainaru M; Harats D; Levy Y; Rubinstein A; Skurnik Y
Isr J Med Sci; 1993 May; 29(5):272-7. PubMed ID: 8314685
[TBL] [Abstract][Full Text] [Related]
8. [Pravastatin in patients with cardiac risk factors. Effects of pravastatin in patients with total serum cholesterol concentrations of 200 to 300 mg/dl (5.2 to 7.8 mmol/l) and two additional atherosclerosis risk factors. Pravastatin Multinational Study Group for Cardiac Risk Patients].
Fortschr Med; 1994 Feb; 112(5):57-64. PubMed ID: 8163252
[TBL] [Abstract][Full Text] [Related]
9. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
Stender S; Schuster H; Barter P; Watkins C; Kallend D;
Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of acipimox and pravastatin in patients with combined hyperlipidemia.
Fogari R; Marasi G; Vanasia A; Zoppi A; Lusardi P; Preti P
Int J Clin Pharmacol Ther; 1997 Feb; 35(2):61-4. PubMed ID: 9147709
[TBL] [Abstract][Full Text] [Related]
11. A controlled trial of pravastatin vs probucol in the treatment of primary hypercholesterolemia.
Gómez-Pérez FJ; Bustamante F; Vergara A; Villaseñor J; Wong B; Rull JA
Rev Invest Clin; 1992; 44(1):53-61. PubMed ID: 1523350
[TBL] [Abstract][Full Text] [Related]
12. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.
Strony J; Hoffman R; Hanson M; Veltri E
Clin Ther; 2008 Dec; 30(12):2280-97. PubMed ID: 19167588
[TBL] [Abstract][Full Text] [Related]
13. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients.
Castaño G; Más R; Arruzazabala ML; Noa M; Illnait J; Fernández JC; Molina V; Menéndez A
Int J Clin Pharmacol Res; 1999; 19(4):105-16. PubMed ID: 10939028
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of pravastatin on serum lipid levels in elderly patients with hypercholesterolemia.
Morimoto S; Koh E; Fukuo K; Higaki J; Ikegami H; Miki T; Hata T; Ogihara T
Clin Ther; 1994; 16(5):793-803. PubMed ID: 7859238
[TBL] [Abstract][Full Text] [Related]
15. Influence of cholesterol lowering on plasma membrane lipids and cationic transport systems.
Lijnen P; Celis H; Fagard R; Staessen J; Amery A
J Hypertens; 1994 Jan; 12(1):59-64. PubMed ID: 8157945
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of primary hypercholesterolemia with pravastatin. A placebo-controlled trial].
Frederiksen SM; Larsen ML; Oxenbøll IB; Pindborg T; Haghfelt T
Ugeskr Laeger; 1993 Sep; 155(36):2794-9. PubMed ID: 8236548
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of the therapeutic efficacy of pravastatin in monothereapy and in association with gemfibrozil in hypercholesterolemia associated with moderate hyperglyceridemia].
Napoli C; Lepore S; Ambrosio G; Chiariello M
Cardiologia; 1992 Nov; 37(11):761-8. PubMed ID: 1298545
[TBL] [Abstract][Full Text] [Related]
18. [An evaluation of the efficacy and safety of pravastatin in patients with primary hypercholesterolemia. A Brazilian open multicenter study].
Giannini SD
Arq Bras Cardiol; 1992 Oct; 59(4):319-27. PubMed ID: 1341189
[TBL] [Abstract][Full Text] [Related]
19. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia.
Krempf M; Rohmer V; Farnier M; Issa-Sayegh M; Corda C; Sirugue I; Gerlinger C; Masseyeff-Elbaz MF
Diabetes Metab; 2000 May; 26(3):184-91. PubMed ID: 10880891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
